Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to American Journal of Obstetrics & Gynecology
- Excess placental soluble fms-like tyrosine kinase 1 (sFlt-11) may contribute to endothelial dysfunction, hypertension, and proteinuria in pre-eclampsia.J Clin Invest. 2003; 111: 649-658
- Circulating angiogenic factors and the risk of pre-eclampsia.N Engl J Med. 2004; 350: 672-683
- Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of pre-eclampsia.J Matern Fetal Neonatal Med. 2011; 24: 1187-1207
- Angiogenic factors as diagnostic tests for preeclampsia: a performance comparison between two commercial immunoassays.Am J Obstet Gynecol. 2011; 205: 469.e1-469.e8
- The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients.Am J Obstet Gynecol. 2012; 206: 58.e1-58.e8
- Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study.Circulation. 2013; 128: 2121-2131
- Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia.Am J Obstet Gynecol. 2013; 208: 287.e1-287.e15
- Competing risks model in screening for preeclampsia by serum placental growth factor and soluble fms-like tyrosine kinase-1 at 30-33 weeks gestation.Fetal Diagn Ther. 2014; 35: 240-248
- Predictive value of the sFlt-1:PlGF ratio in women with suspected pre-eclampsia.N Engl J Med. 2016; 374: 13-22
- A comparison of the diagnostic utility of the sFlt-1/PlGF ratio versus PlGF alone for the detection of preeclampsia/HELLP syndrome.Hypertens Pregnancy. 2016; 35: 295-305
- Development of pre-eclampsia within 4 weeks of sFlt-1/PlGF ratio > 38: comparison of performance at 31-34 vs 35-37 weeks gestation.Ultrasound Obstet Gynecol. 2017; 49: 209-212
- Competing risks model in screening for preeclampsia by maternal characteristics and medical history.Am J Obstet Gynecol. 2015; 213: 62.e1-62.e10
- Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation.Am J Obstet Gynecol. 2016; 214: 103.e1-103.e12
- Predictive performance of the competing risk model in screening for preeclampsia.Am J Obstet Gynecol. 2019; 220: 199.e1-199.e13
- Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 19–24 weeks gestation.Am J Obstet Gynecol. 2016; 214: 619.e1-619.e17
- Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 30–34 weeks gestation.Am J Obstet Gynecol. 2016; 215: 87.e1-87.e17
- Competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 35–37 weeks gestation.Ultrasound Obstet Gynecol. 2016; 48: 72-79
- Proposed clinical management of pregnancies after combined screening for preeclampsia at 35–37 weeks gestation.Ultrasound Obstet Gynecol. 2017; 50: 383-387
- Screening for pre-eclampsia at 35-37 weeks gestation.Ultrasound Obstet Gynecol. 2018; 52: 501-506
- Comparison of screening for pre-eclampsia at 31-34 weeks gestation by sFlt-1/PlGF ratio and a method combining maternal factors with sFlt-1 and PlGF.Ultrasound Obstet Gynecol. 2017; 49: 201-208
- Protocol for measurement of mean arterial pressure at 11-13 weeks gestation.Fetal Diagn Ther. 2012; 31: 42-48
- A critical evaluation of sonar crown rump length measurements.BJOG. 1975; 82: 702-710
- Fetal biometry at 14–40 weeks gestation.Ultrasound Obstet Gynecol. 1994; 4: 34-38
- The classification and diagnosis of the hypertensive disorders of pregnancy: Statement from the international society for the study of hypertension in pregnancy (ISSHP).Hypertens Pregnancy. 2001; 20 (IX–XIV)
- American College of Obstetricians and Gynecologists and the Task Force on Hypertension in Pregnancy. Hypertension in pregnancy.Obstet Gynecol. 2013; 122: 1122-1131
- R. A language and environment for statistical computing.R Foundation for Statistical Computing, Vienna, Austria2011 (ISBN 3-900051-07-0. Available at:)Accessed December 20, 2018)
- pROC: an open-source package for R and S+ to analyze and compare ROC curves.BMC Bioinformatics. 2011; 12: 77-84
- Maternal serum placental growth factor at 12, 22, 32 and 36 weeks gestation in screening for pre-eclampsia.Ultrasound Obstet Gynecol. 2016; 47: 472-477
- Maternal serum soluble fms-like tyrosine kinase-1 at 12, 22, 32 and 36 weeks gestation in screening for pre-eclampsia.Ultrasound Obstet Gynecol. 2016; 47: 478-483
- Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia.N Engl J Med. 2017; 377: 613-622
- Aspirin for Evidence-Based Preeclampsia Prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia.Am J Obstet Gynecol. 2017; 217: 685.e1-685.e5
- Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history.Am J Obstet Gynecol. 2017; 217: 585.e1-585.e5
- Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis.Am J Obstet Gynecol. 2018; 218: 287-293.e1
- Screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks gestation.Ultrasound Obstet Gynecol. 2018; 52: 186-195
Supported by a grant from the Fetal Medicine Foundation (Charity No: 1037116). The reagents and equipment for the measurement of serum placental growth factor and soluble fms-like tyrosine kinase-1 were provided by Thermo Fisher Scientific.
These bodies had no involvement in the study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.
The authors report no conflict of interest.
Cite this article as: Ciobanu A, Wright A, Panaitescu A, et al. Prediction of imminent preeclampsia at 35–37 weeks gestation. Am J Obstet Gynecol 2019;220:584.e1-11.